These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 1862210)

  • 1. Steady-state plasma level prediction for haloperidol from a single test dose.
    Javaid JI; Janicak PG; Hedeker D; Sharma RP; Davis JM
    Psychopharmacol Bull; 1991; 27(1):83-8. PubMed ID: 1862210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of haloperidol steady-state levels in plasma after a single test dose.
    Javaid JI; Janicak PG; Sharma RP; Leach AM; Davis JM; Wang Z
    J Clin Psychopharmacol; 1996 Feb; 16(1):45-50. PubMed ID: 8834418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of steady-state concentrations of valproic acid as determined from single plasma concentrations after the first dose.
    May CA; Garnett WR
    Clin Pharm; 1983; 2(2):143-7. PubMed ID: 6411412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of route of administration on haloperidol plasma levels in psychotic patients.
    Bianchetti G; Zarifian E; Poirier-Littre MF; Morselli PL; Deniker P
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):324-7. PubMed ID: 7429678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
    Chang WH; Lin SK; Jann MW
    J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood levels of haloperidol in schizophrenic patients.
    Shvartsburd A; Dekirmenjian H; Smith RC
    J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma level monitoring of psychotropic drugs in children. I-Haloperidol (author's transl)].
    Dugas M; Zarifian E; Le Heuzey MF; Regnier N; Durand G; Bianchetti G; Morselli PL
    Nouv Presse Med; 1982 Jun; 11(29):2201-4. PubMed ID: 7110982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid desipramine dose adjustment using 24-hour levels.
    Nelson JC; Jatlow PI; Mazure C
    J Clin Psychopharmacol; 1987 Apr; 7(2):72-7. PubMed ID: 3584524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
    Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL
    J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Haloperidol. Plasma monitoring and hormonal effects of treatment].
    Goyot C; Debray Q; Dugas M; Guay C; Giraud J; Grenier J
    Pathol Biol (Paris); 1985 Dec; 33(10):999-1004. PubMed ID: 2937009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.